{"id":44126,"date":"2025-10-22T20:42:33","date_gmt":"2025-10-22T12:42:33","guid":{"rendered":"https:\/\/flcube.com\/?p=44126"},"modified":"2025-10-22T20:42:33","modified_gmt":"2025-10-22T12:42:33","slug":"gfh375-enters-phase-ib-ii-at-peking-university-genfleet-targets-kras-g12d","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44126","title":{"rendered":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D"},"content":{"rendered":"\n<p><strong>GenFleet Therapeutics (Shanghai) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2595:HKG\">HKG: 2595<\/a>) today announced that the first patient has been enrolled in a <strong>Phase\u202fIb\/II<\/strong> study of its oral KRAS\u202fG12D inhibitor, <strong>GFH375<\/strong>, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for <strong>pancreatic ductal adenocarcinoma (PDAC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class Oral KRAS\u202fG12D Inhibitor<\/strong> \u2013 GFH375 is a highly selective, non\u2011covalent inhibitor that blocks KRAS\u202fG12D\u2011mediated effector signaling.<\/li>\n\n\n\n<li><strong>Dual\u2011Regimen Design<\/strong> \u2013 Combines GFH375 with either the EGFR blocker cetuximab or standard chemotherapy.<\/li>\n\n\n\n<li><strong>Strategic Licensing<\/strong> \u2013 GenFleet\u2019s partnership with Verastem grants exclusive outside\u2011China rights to GFH375, while GenFleet retains mainland China rights.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-pathway\"><strong>Clinical Development Pathway<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Status<\/th><th>Milestones<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fIb\/II<\/strong><\/td><td>Enrollment launched<\/td><td>Primary endpoint: objective response rate (ORR) in KRAS\u202fG12D+ solid tumors<\/td><\/tr><tr><td><strong>Chemotherapy Arm<\/strong><\/td><td>Planned first\u2011line PDAC therapy<\/td><td>Expected to progress to Phase\u202fIII if ORR \u2265 35\u202f%<\/td><\/tr><tr><td><strong>Cetuximab Arm<\/strong><\/td><td>Evaluating synergy with EGFR inhibition<\/td><td>Secondary endpoints: progression\u2011free survival (PFS), overall survival (OS)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Pre\u2011clinical data demonstrate a robust, dose\u2011dependent antitumor effect and a favorable kinase\u2011selectivity profile, underscoring GFH375\u2019s potential to transform KRAS\u2011driven oncology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-collaboration-with-verastem\"><strong>Strategic Collaboration with Verastem<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Three\u2011Product RAS\/MAPK Portfolio<\/strong> \u2013 GenFleet and Verastem have signed a licensing and early\u2011stage collaboration for three RAS\u2011driven agents.<\/li>\n\n\n\n<li><strong>Exclusive License Option<\/strong> \u2013 Verastem holds an exclusive option to license each product upon meeting predefined Phase\u202fI milestones.<\/li>\n\n\n\n<li><strong>Geographic Rights<\/strong> \u2013 Verastem gains development and commercialization rights outside Greater China; GenFleet retains rights within mainland China.<\/li>\n\n\n\n<li><strong>GFH375 Lead Program<\/strong> \u2013 Selected as the partnership\u2019s flagship in December\u202f2023, GFH375\u2019s license marks the first product to materialize from the collaboration.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102200028_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102200028_c.\"><\/object><a id=\"wp-block-file--media-31380603-93db-4304-9576-3644a31cd64b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102200028_c.pdf\">2025102200028_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102200028_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-31380603-93db-4304-9576-3644a31cd64b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,1682,4345],"class_list":["post-44126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-genfleet-therapeutics","tag-hkg-2595"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44126\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D\" \/>\n<meta property=\"og:description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44126\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:42:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GFH375 Enters Phase\u202fIb\\\/II at Peking University: GenFleet Targets KRAS\u202fG12D\",\"datePublished\":\"2025-10-22T12:42:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126\"},\"wordCount\":333,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2209.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"GenFleet Therapeutics\",\"HKG: 2595\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44126#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44126\",\"name\":\"GFH375 Enters Phase\u202fIb\\\/II at Peking University: GenFleet Targets KRAS\u202fG12D - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2209.webp\",\"datePublished\":\"2025-10-22T12:42:33+00:00\",\"description\":\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\\\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44126\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2209.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2209.webp\",\"width\":1080,\"height\":608,\"caption\":\"GFH375 Enters Phase\u202fIb\\\/II at Peking University: GenFleet Targets KRAS\u202fG12D\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GFH375 Enters Phase\u202fIb\\\/II at Peking University: GenFleet Targets KRAS\u202fG12D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D - Insight, China&#039;s Pharmaceutical Industry","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44126","og_locale":"en_US","og_type":"article","og_title":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D","og_description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).","og_url":"https:\/\/flcube.com\/?p=44126","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T12:42:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44126#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44126"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D","datePublished":"2025-10-22T12:42:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44126"},"wordCount":333,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","keywords":["Cancer","Clinical trial approval \/ initiation","GenFleet Therapeutics","HKG: 2595"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44126#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44126","url":"https:\/\/flcube.com\/?p=44126","name":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44126#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","datePublished":"2025-10-22T12:42:33+00:00","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled in a Phase\u202fIb\/II study of its oral KRAS\u202fG12D inhibitor, GFH375, at Peking University Cancer Hospital. The trial evaluates two combination regimens\u2014GFH375 with cetuximab and GFH375 with chemotherapy\u2014targeting advanced solid tumors harboring the KRAS\u202fG12D mutation. The chemotherapy\u2011based arm is slated to become a first\u2011line treatment for pancreatic ductal adenocarcinoma (PDAC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44126#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44126"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44126#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","width":1080,"height":608,"caption":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GFH375 Enters Phase\u202fIb\/II at Peking University: GenFleet Targets KRAS\u202fG12D"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2209.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44126"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44126\/revisions"}],"predecessor-version":[{"id":44129,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44126\/revisions\/44129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44128"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}